Abstract
Cerebral edema causes intracranial hypertension (ICH) which leads to severe outcome of patients in the clinical setting. Effective anti-edema therapy may significantly decrease the mortality in a variety of neurological conditions. At present drug treatment is a cornerstone in the management of cerebral edema. Osmotherapy has been the mainstay of pharmacologic therapy. Mannitol and hypertonic saline (HS) are the most commonly used osmotic agents. The relative safety and efficacy of HS and mannitol in the treatment of cerebral edema and reduction of enhanced ICP have been demonstrated in the past decades. Apart from its osmotic force, HS exerts anti-edema effects partly through inhibition of Na+-K+-2Cl- Cotransporter-1 (NKCC1) and aquaporin 4 (AQP4) expression in astrocytes. Melatonin may also reduce brain edema and exert neuroprotective effect on several central nervous system diseases through inhibition of inflammatory response. The inhibitors of Na/H exchanger, NKCC and AQP4 may attenuate brain edema formation through inhibition of excessive transportation of ion and water from blood into the cerebral tissue. In this review we survey some of the most recent findings in the drug treatment of brain edema focusing on the use of osmotherapy, melatonin and inhibitors of ion cotransporters and water channels. A better understanding of the molecular mechanism of these agents would help to improve in the clinical management of patients with brain edema.
Keywords: AQP4 inhibitor, bumetanide, cerebral edema, hypertonic saline, mannitol, melatonin, Na/H exchanger inhibitor.
Mini-Reviews in Medicinal Chemistry
Title:Progress in Drug Treatment of Cerebral Edema
Volume: 16 Issue: 11
Author(s): Y. Y. Deng, F. C. Shen, D. Xie, Q. P. Han, M. Fang, C. B. Chen and H. K. Zeng
Affiliation:
Keywords: AQP4 inhibitor, bumetanide, cerebral edema, hypertonic saline, mannitol, melatonin, Na/H exchanger inhibitor.
Abstract: Cerebral edema causes intracranial hypertension (ICH) which leads to severe outcome of patients in the clinical setting. Effective anti-edema therapy may significantly decrease the mortality in a variety of neurological conditions. At present drug treatment is a cornerstone in the management of cerebral edema. Osmotherapy has been the mainstay of pharmacologic therapy. Mannitol and hypertonic saline (HS) are the most commonly used osmotic agents. The relative safety and efficacy of HS and mannitol in the treatment of cerebral edema and reduction of enhanced ICP have been demonstrated in the past decades. Apart from its osmotic force, HS exerts anti-edema effects partly through inhibition of Na+-K+-2Cl- Cotransporter-1 (NKCC1) and aquaporin 4 (AQP4) expression in astrocytes. Melatonin may also reduce brain edema and exert neuroprotective effect on several central nervous system diseases through inhibition of inflammatory response. The inhibitors of Na/H exchanger, NKCC and AQP4 may attenuate brain edema formation through inhibition of excessive transportation of ion and water from blood into the cerebral tissue. In this review we survey some of the most recent findings in the drug treatment of brain edema focusing on the use of osmotherapy, melatonin and inhibitors of ion cotransporters and water channels. A better understanding of the molecular mechanism of these agents would help to improve in the clinical management of patients with brain edema.
Export Options
About this article
Cite this article as:
Y. Deng Y., C. Shen F., Xie D., P. Han Q., Fang M., B. Chen C. and K. Zeng H., Progress in Drug Treatment of Cerebral Edema, Mini-Reviews in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1389557516666160304151233
DOI https://dx.doi.org/10.2174/1389557516666160304151233 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tityus serrulatus Scorpion Venom and Toxins: An Overview
Protein & Peptide Letters Metabolic Syndrome Targets
Current Drug Targets - CNS & Neurological Disorders Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis
Current Pharmaceutical Design Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design A Review of QSAR studies to Discover New Drug-like Compounds Actives Against Leishmaniasis and Trypanosomiasis
Current Topics in Medicinal Chemistry Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Early Post-Operative Neuroimaging After Surgery for Malignant Glioma
Current Medical Imaging Resveratrol Protects Endothelial Cells from Rapid Stretch Injury and Hypoxia In Vitro
Current Drug Therapy Heme Oxygenase-1 in Lung Disease
Current Drug Targets Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
Current Pharmaceutical Design Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Targeted Tumor Therapies at a Glance
Current Drug Targets Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets Restless Legs Syndrome in Children: A Review and Update on Pharmacological Options
Current Pharmaceutical Design Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies